CD4 and neoplasm: Treatment of ascophyllan led to substantial increases in the proportions of IFN-γ- and TNF-α-producing CD4 and CD8 T cells in the spleen and tumor drLN, whereas IL-4- or IL-17-producing CD4 and CD8 T cells were not increased by ascophyllan treatment (Figure 2A).